Antonio Girolami

List of Publications by Year
in descending order

103	1,708	471061 17	315357 38
papers	citations	h-index	g-index

105	105	105	1561
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Peculiar Congenital Factor VII Defect with the Proposita and Her Mother Showing the Same Compound Heterozygosity for Thr384Met and Arg413Gln. Acta Haematologica, 2021, 144, 100-104.	0.7	2
2	A comment on congenital prothrombin abnormalities associated with thrombosis but not with bleeding. Journal of Thrombosis and Thrombolysis, 2021, 51, 513-515.	1.0	0
3	Homozygous Prekallikrein Deficiency in the USA: Several Patients but Still Few Mutation Studies. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962199877.	0.7	1
4	A Rare Cause of Isolated Prothrombin Time Prolongation. Journal of Pediatric Hematology/Oncology, 2021, Publish Ahead of Print, e1248-e1250.	0.3	0
5	African and African-American Contribution to the Knowledge of the FVII Padua (Arg304Gln) Defect. Journal of the National Medical Association, 2020, 112, 109-110.	0.6	0
6	Increased Prevalence of Reported Cases of Congenital Prekallikrein Deficiency Among African Americans as Compared With the General Population of the United States. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962091830.	0.7	5
7	The slow but progressive disappearance of the patients with the Pro343Ser (FX Friuli) mutation. British Journal of Haematology, 2020, 191, e50-e52.	1.2	0
8	Prevalence of Cardiovascular Disorders in African-Americans With Congenital Prekallikrein Deficiency Versus Caucasians-Americans With the Same Defect. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962097248.	0.7	1
9	Long-term safety outcomes of prekallikrein (Fletcher factor) deficiency: A systematic literature review of case reports. Allergy and Asthma Proceedings, 2020, 41, 10-18.	1.0	9
10	An acquired prekallikrein deficiency can be diagnosed only after a sure exclusion of a congenital condition. Blood Coagulation and Fibrinolysis, 2020, Publish Ahead of Print, 419.	0.5	0
11	The Dysprothrombinemias due to Arg596 Mutations: A Conundrum With No Bleeding Tendency and Venous Thrombosis due to Antithrombin Resistance. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961984170.	0.7	1
12	Heterozygous FXII deficiency is not associated with an increased incidence of thrombotic events: Results of a long term study. Blood Cells, Molecules, and Diseases, 2019, 77, 8-11.	0.6	5
13	New data on FII, FV, FIX and thrombomodulin defects: blood keeps clotting in normal and in peculiar ways. Hematology, 2019, 24, 232-237.	0.7	0
14	Thrombotic events in severe FXII deficiency in comparison with unaffected family members during a long observation period. Journal of Thrombosis and Thrombolysis, 2019, 47, 481-485.	1.0	14
15	Factor X Deficiency Due to a Compound Heterozygosis Between a New Mutation (Gla72Asp) in Exon 2 Hematological Disorders Drug Targets, 2019, 19, 169-173.	0.2	0
16	Thrombotic Events in Homozygotes with a Proven or Highly Probable Arg304Gln Factor VII Mutation Hematological Disorders Drug Targets, 2019, 19, 233-238.	0.2	0
17	Prothrombin: Another Clotting Factor After FV That Is Involved Both in Bleeding and Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 845-849.	0.7	10
18	Factor X Friuli Coagulation Disorder: Almost 50 Years Later. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 33-40.	0.7	3

#	Article	IF	Citations
19	A structureâ€“function analysis in patients with prekallikrein deficiency. Hematology, 2018, 23, 346-350.	0.7	4
20	Thrombotic and Hemorrhagic Conditions Due to a Gain of Function of Coagulation Proteins: A Special Type of Clotting Disorders. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 560-565.	0.7	1
21	Congenital prothrombin defects: they are not only associated with bleeding but also with thrombosis: a new classification is needed. Hematology, 2018, 23, 105-110.	0.7	13
22	Vitamin K-Dependent Coagulation Factors That May be Responsible for Both Bleeding and Thrombosis (FII, FVII, and FIX). Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 42S-47S.	0.7	22
23	Cardiovascular diseases in congenital prekallikrein deficiency. Blood Coagulation and Fibrinolysis, 2018, 29, 423-428.	0.5	8
24	Bleeding manifestations in heterozygotes with congenital FVII deficiency: a comparison with unaffected family members during a long observation period. Hematology, 2017, 22, 375-379.	0.7	13
25	Bleeding manifestations in heterozygotes with prothrombin deficiency or abnormalities vs. unaffected family members as observed during a long follow-up study. Blood Coagulation and Fibrinolysis, 2017, 28, 623-626.	0.5	5
26	Role of replacement therapy in the evaluation of thrombosis occurring in congenital bleeding conditions. Thrombosis and Haemostasis, 2017, 117, 2006-2007.	1.8	1
27	Ischemic Strokes in Congenital Bleeding Disorders: Comparison with Myocardial Infarction and other Acute Coronary Syndromes. Cardiovascular & Hematological Disorders Drug Targets, 2016, 16, 6-12.	0.2	1
28	Pulmonary embolism in congenital bleeding disorders. Blood Coagulation and Fibrinolysis, 2016, 27, 517-525.	0.5	6
29	Prevalence of bleeding manifestations in 128 heterozygotes for Factor X deficiency, mainly for <scp>FX</scp> Friuli, matched versus 128 unaffected family members, during a long sequential observation period (23.5 years). European Journal of Haematology, 2016, 97, 547-553.	1.1	7
30	A family with factor X deficiency from Argentina. Blood Coagulation and Fibrinolysis, 2016, 27, 732-736.	0.5	3
31	Acquired Isolated FVII Deficiency. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 705-711.	0.7	18
32	Prevalence of hypertension and its complications in congenital prekallikrein deficiency. Blood Coagulation and Fibrinolysis, 2015, 26, 560-563.	0.5	13
33	Myocardial Infarctions and Other Acute Coronary Syndromes in Rare Congenital Bleeding Disorders. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 359-364.	0.7	6
34	Complex History of the Discovery and Characterization of Congenital Factor X Deficiency. Seminars in Thrombosis and Hemostasis, 2015, 41, 359-365.	1.5	11
35	Venous thrombosis in von Willebrand disease as observed in one centre and as reported in the literature. Blood Coagulation and Fibrinolysis, 2015, 26, 54-58.	0.5	14
36	The Old and the New in Prekallikrein Deficiency: Historical Context and a Family from Argentina with PK Deficiency due to a New Mutation (Arg541Gln) in Exon 14 Associated with a Common Polymorphysm (Asn124Ser) in Exon 5. Seminars in Thrombosis and Hemostasis, 2014, 40, 592-599.	1.5	10

#	Article	IF	Citations
37	Bleeding manifestations apparently unrelated to coagulation or other organic disorders: A tentative classification and diagnostic clues. Hematology, 2014, 19, 293-298.	0.7	6
38	A family with factor-XI deficiency due to a compound heterozygosis between Gln 47 Pro (new) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702	0.5	0
39	Discrepant ratios of arterial versus venous thrombosis in hemophilia A as compared with hemophilia B. Journal of Thrombosis and Thrombolysis, 2014, 37, 293-297.	1.0	12
40	Discrepant ratios of arterial vs. venous thrombosis in hemophilias <scp>A</scp> and <scp>B</scp> as compared to <scp>FVII</scp> deficiency. European Journal of Haematology, 2013, 91, 152-156.	1.1	10
41	Occurrence of thrombosis in congenital thrombocytopenic disorders. Blood Coagulation and Fibrinolysis, 2013, 24, 18-22.	0.5	19
42	Arterial and Venous Thromboses in Patients With Idiopathic (Immunological) Thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 613-618.	0.7	18
43	Congenital Thrombophilia and Intracardiac Thrombosis: Probably an Underdiagnosed Event. Cardiology Research, 2013, 4, 109-115.	0.5	7
44	Recombinant FVIIa concentrate-associated thrombotic events in congenital bleeding disorders other than hemophilias. Hematology, 2012, 17, 346-349.	0.7	14
45	Myocardial infarction in two cousins heterozygous for ASN41HIS autosomal dominant variant of Bernardâ€“Soulier syndrome. Journal of Thrombosis and Thrombolysis, 2012, 34, 513-517.	1.0	10
46	Rare and Unusual Bleeding Manifestations in Congenital Bleeding Disorders. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 121-127.	0.7	11
47	A cluster of factor XIâ€deficient patients due to a new mutation (Ile 436 Lys) in northeastern Italy*. European Journal of Haematology, 2012, 88, 229-236.	1.1	4
48	Worldwide diffusion of FVII Arg304Gln coagulation defect (FVII Padua)*. European Journal of Haematology, 2011, 86, 135-139.	1.1	12
49	Congenital FVII deficiency and thrombotic events after replacement therapy. Journal of Thrombosis and Thrombolysis, 2011, 32, 362-367.	1.0	31
50	Thrombotic events in MYH9 gene-related autosomal macrothrombocytopenias (old Mayâ€“Hegglin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.0	14
51	The lack of ties between north-eastern Italy and African-Americans suggest a multi-founder effect for FVII Padua (Arg304Gln) disorder. Blood Coagulation and Fibrinolysis, 2010, 21, 775-776.	0.5	5
52	The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency. Journal of Thrombosis and Thrombolysis, 2010, 29, 299-302.	1.0	17
53	A large family from Argentina with Prekallikrein deficiency due to a compound heterozygosis (T) Tj ETQq1 1 0.784314 rgBT /Overlock Hematology, 2010, 85, 363-366.	2.0	10
54	Congenital prekallikrein deficiency. Expert Review of Hematology, 2010, 3, 685-695.	1.0	49

#	Article	IF	Citations
55	The clinical and laboratory significance of cases of congenital FX deficiency due to defects in the Gla-domain. Hematology, 2009, 14, 177-181.	0.7	6
56	The association of a mild FXII deficiency with myocardial infarction and venous thrombosis is completely unjustified. Journal of Thrombosis and Thrombolysis, 2009, 27, 454-455.	1.0	2
57	Arterial thrombosis and drospirenone-containing pill (Yasmin). Is the pill to be absolutely avoided by women who smoke?. Journal of Thrombosis and Thrombolysis, 2008, 26, 163-164.	1.0	5
58	Congenital factor X deficiencies with a defect only or predominantly in the extrinsic or in the intrinsic system: A critical evaluation. American Journal of Hematology, 2008, 83, 668-671.	2.0	28
59	Different genotypes are responsible for the normal Russell viper venom assays seen in some cases of congenital factor X deficiency. American Journal of Hematology, 2008, 83, 884-885.	2.0	8
60	Genetic study in patients with factor XII deficiency: a report of three new mutations exon 13 (Q501STOP), exon 14 (P547L) and â€“13C>T promoter region in three compound heterozygotes. Blood Coagulation and Fibrinolysis, 2008, 19, 639-643.	0.5	17
61	Arterial thrombosis in young women after ovarian stimulation: case report and review of the literature. Journal of Thrombosis and Thrombolysis, 2007, 24, 169-174.	1.0	38
62	Retinal central artery occlusion in a young woman after ten days of a drospirenone-containing oral contraceptive (Yasmin). Thrombosis and Haemostasis, 2007, 98, 473-474.	1.8	3
63	Retinal central artery occlusion in a young woman after ten days of a drospirenone-containing oral contraceptive (Yasmin). Thrombosis and Haemostasis, 2007, 98, 473-4.	1.8	4
64	Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases. Journal of Thrombosis and Thrombolysis, 2006, 21, 279-284.	1.0	67
65	Pregnancy and Oral Contraceptives in Congenital Bleeding Disorders of the Vitamin K- Dependent Coagulation Factors. Acta Haematologica, 2006, 115, 58-63.	0.7	14
66	Unusual longevity in a patient with factor X Friuli coagulation disorder. Thrombosis and Haemostasis, 2005, 93, 385-387.	1.8	7
67	FXII deficiency is neither a cause of thrombosis nor a protection from thrombosis. American Journal of Ophthalmology, 2005, 139, 578-579.	1.7	3
68	Unusual longevity in a patient with factor X Friuli coagulation disorder. Thrombosis and Haemostasis, 2005, 93, 385-7.	1.8	1
69	Rebuttal: Factor XII levels, factor XII 46 C>T polymorphism and venous thrombosis: a word of caution is needed. Thrombosis and Haemostasis, 2004, 92, 892-893.	1.8	6
70	A New Mutation (Arg251 Trp) in the Ca2+ Binding Site of Factor X Protease Domain Appears to be Responsible for the Defect in the Extrinsic Pathway Activation of Factor X Padua. Clinical and Applied Thrombosis/Hemostasis, 2004, 10, 5-8.	0.7	10
71	Rebuttal: factor XII levels, factor XII 46 C>T polymorphism and venous thrombosis: a word of caution is needed. Thrombosis and Haemostasis, 2004, 92, 892-3; author reply 894-5.	1.8	3
72	Proposal of a Flow Chart for Thrombosis-Free Oral Contraceptive Therapy. Clinical and Applied Thrombosis/Hemostasis, 2003, 9, 33-37.	0.7	3

#	Article	IF	Citations
73	An Association between Atherosclerosis and Venous Thrombosis. New England Journal of Medicine, 2003, 348, 1435-1441.	13.9	574
74	A novel type I factor X variant (factor X Cys350Phe) due to loss of a disulfide bond in the catalytic domain. Blood Coagulation and Fibrinolysis, 2003, 14, 401-405.	0.5	9
75	Severe prekallikrein (Fletcher factor) deficiency due to a compound heterozygosis (383Trp stop codon) Tj ETQq1 1 0.784314 rgBT /O	1.8	47
76	Clinical aspects of venous thrombophilia. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 258-262.	0.5	9
77	Tentative Guidelines and Practical Suggestions to Avoid Venous Thromboembolism During Oral Contraceptive Therapy. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 97-102.	0.7	6
78	Conformation sensitive gel electrophoresis for detection of factor X gene mutations. Thrombosis Research, 2002, 107, 51-54.	0.8	11
79	A Dysfunctional Factor X (Factor X San Giovanni Rotondo) Present at Homozygous and Double Heterozygous Level: Identification of a Novel Microdeletion (delC556) and Missense Mutation (Lys408âT'Asn) in the Factor X Gene. Thrombosis Research, 2001, 101, 219-230.	0.8	25
80	A New Factor X Defect (Factor X Padua 3). Thrombosis Research, 2001, 104, 257-264.	0.8	15
81	Prothrombotic Activity of Oral Contraceptives in Patients With Congenital Thrombophilia Varies With the Defect. Clinical and Applied Thrombosis/Hemostasis, 2001, 7, 76-77.	0.7	6
82	Platelet Activation With Unfractionated Heparin at Therapeutic Concentrations and Comparison With Low-Molecular-Weight Heparin and With a Direct Thrombin Inhibitor. Circulation, 1999, 99, 3323-3326.	1.6	5
83	Combined Factor V and Factor VII Deficiency Due to an Independent Segregation of the Two Defects. Clinical and Applied Thrombosis/Hemostasis, 1999, 5, 136-138.	0.7	10
84	Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. British Journal of Haematology, 1998, 103, 1045-1050.	1.2	54
85	Factor V Leiden (Activated Protein C Resistance) Versus Factor V Deficiency in Padua, Italy. Clinical and Applied Thrombosis/Hemostasis, 1998, 4, 201-204.	0.7	1
86	Abnormally large von Willebrand factor multimers in Henoch-SchÃ¶nlein purpura. , 1996, 51, 7-11.		17
87	Antiphospholipid Antibodies, Recurrent Thromboembolism, and Intensity of Warfarin Anticoagulation. Thrombosis and Haemostasis, 1996, 75, 859-859.	1.8	43
88	Prothrombin time using thromboplastins of different origin in hemophilia BM patients. American Journal of Hematology, 1994, 47, 245-246.	2.0	0
89	The dysfunction of coagulation factor VIIPadua results from substitution of arginine-304 by glutamine. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1993, 1172, 301-305.	2.4	21
90	Comparison of Real-Time B-Mode Ultrasonography and Doppler Ultrasound with Contrast Venography in the Diagnosis of Venous Thrombosis in Symptomatic Outpatients. Thrombosis and Haemostasis, 1993, 70, 404-407.	1.8	42

#	Article	IF	Citations
91	Thrombotic and Haemorrhagic Complications in Patients with Heart Valve Prostheses: A More Complex Matter Than Proper Prothrombin Time Ratios. Thrombosis and Haemostasis, 1993, 70, 878-878.	1.8	0
92	Unusual Association of Hairy Cell Leukemia and Monoclonal Large Granular Lymphocyte Proliferation. Leukemia and Lymphoma, 1990, 2, 433-436.	0.6	0
93	Bilateral Ileofemoral Thrombophlebitis after Ten Contraceptive Pills in a 25-Year-Old Woman with Antithrombin III Deficiency. Acta Haematologica, 1988, 79, 118-119.	0.7	12
94	Full dose dipyridamole significantly improves thrombocytopenia in liver cirrhosis. Blut, 1987, 55, 63-64.	1.2	5
95	The Incidence of Thrombotic Manifestations in AT III Abnormalities. Thrombosis and Haemostasis, 1987, 57, 123-123.	1.8	11
96	Tentative and Updated Classification of Factor X Variants. Acta Haematologica, 1986, 75, 58-59.	0.7	18
97	The Release of Platelet Factor 4 (PF4) Induced by Heparin and Related Glycosaminoglycans (GAGs). Thrombosis and Haemostasis, 1984, 52, 094-094.	1.8	1
98	CROSSED IMMUNOELECTROPHORESIS IN THE STUDY OF ABNORMAL ANTITHROMBINS III: BEHAVIOUR OF AT III TRENTO. British Journal of Haematology, 1983, 55, 559-561.	1.2	2
99	The release of Î²- thromboglobulin and platelet factor 4 during extracorporeal circulation for open heart surgery. European Journal of Clinical Investigation, 1981, 11, 165-169.	1.7	45
100	Heparins and Release. Thrombosis and Haemostasis, 1980, 44, 105-105.	1.8	4
101	Factor X Friuli Coagulation Disorder. Acta Haematologica, 1976, 56, 27-38.	0.7	9
102	Abnormal Factor X (Factor X Friuli) Coagulation Disorder. The Heterozygote Population. Acta Haematologica, 1974, 51, 40-50.	0.7	20
103	Hemorrhagic varicella in parahemophilia. Blut, 1972, 25, 293-301.	1.2	4